Current Therapeutic Strategies for Trachoma
- Authors: Himani Bajaj1, Sindhu Agarwal2, Anjali Sharma3, Mayank Yadav4, Md. Arif Naseer5
-
View Affiliations Hide AffiliationsAffiliations: 1 AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India 2 AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India 3 Guru Gobind Singh College of Pharmacy, Yamunanagar, Haryana, India 4 AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India 5 AVIPS, Shobhit University, Gangoh, Saharanpur, UP, India
- Source: Emerging Approaches to Tackle Neglected Diseases: From Molecule to End Product , pp 182-199
- Publication Date: June 2024
- Language: English
Current Therapeutic Strategies for Trachoma, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815196863/chapter-9-1.gif
As a result of persistent follicular conjunctivitis brought on by Chlamydia trachomatis and consequent corneal scarring, about 6 million people have irreparable blindness. Chlamydia trachomatis is a bacterium that causes trachoma, an eye infection. Early signs include eyelid itchiness and irritation, whereas advanced signs include swollen eyelids, pus oozing from the eyes, photophobia (light sensitivity), discomfort in the eye, and vision issues. Using the SAFE strategy, the WHO is driving an international campaign to eradicate Blinding Trachoma. Trichiasis surgery, antibiotic treatment for infection, hygiene promotion on the face, and environmental changes to improve air quality are all part of this. The best antibacterial medication for widespread distribution is oral azithromycin.
-
From This Site
/content/books/9789815196863.chapter-9dcterms_subject,pub_keyword-contentType:Journal105
